SCHEDULE 13G/A: Tang Capital Group Discloses Passive 0.6% Stake in ITeos Therapeutics
Beneficial Ownership Disclosure
Tang Capital Management, along with its affiliated entities and Kevin Tang, has filed an amended Schedule 13G, revealing a passive 0.6% ownership stake in ITeos Therapeutics, Inc. as of December 31, 2024.
Summary
- The filing is an Amendment No. 1 to Schedule 13G for ITeos Therapeutics, Inc. (Issuer).
- The reporting persons are Tang Capital Management, LLC (TCM), Kevin Tang, Tang Capital Partners, LP (TCP), Tang Capital Partners III, Inc. (TCP III), and Tang Capital Partners IV, Inc. (TCP IV).
- The aggregate amount beneficially owned by the reporting persons is 221,716 shares of Common Stock.
- This beneficial ownership represents 0.6% of ITeos Therapeutics, Inc.'s outstanding Common Stock.
- The percentage is calculated based on 36,533,918 shares of Common Stock outstanding as of November 7, 2024, as reported in the Issuer's Form 10-Q filed on November 12, 2024.
- TCM, Kevin Tang, and TCP share both voting and dispositive power over the 221,716 shares.
- TCP III and TCP IV reported 0 shares beneficially owned and 0.0% of the class.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing passive ownership, providing factual information without indicating positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Management Comments
- The reporting persons certify that, to the best of their knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing is a routine disclosure of passive ownership and does not provide broader industry context.
Stakeholder Impact
- Limited impact on shareholders due to the small (0.6%) and passive nature of the reported stake, indicating no intent to influence control of the issuer.
Key Dates
| Date | Description |
|---|---|
| 2024-11-07 | Date as of which 36,533,918 shares of Common Stock were outstanding, as reported by the Issuer. |
| 2024-11-12 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this statement (reporting period end). |
| 2025-02-14 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
ITeos Therapeutics, Tang Capital Management, Kevin Tang, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.